Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies

Launched by THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL COLLEGE · Aug 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a specific blood marker called serum histone succinylation can help doctors better predict how patients with blood cancers—like leukemia and lymphoma—will respond to treatments such as chemotherapy, stem cell transplants, or immunotherapy. The goal is to see if measuring this marker can provide useful information about the disease and treatment outcomes, potentially helping with early detection and personalized care.

Adults 18 years and older who have been diagnosed with blood cancer and need treatment may be eligible to participate. The study will also include a group of healthy adults without cancer for comparison. Participants will have a blood sample taken to measure this marker and will be followed to see how their treatment works. Pregnant women, people with severe mental health issues, or those who have difficulty communicating will not be able to join. This study is not yet recruiting but aims to include about 200 patients with blood cancers and 200 healthy volunteers.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria tumor group
• • 1. ≥ 18 years old , regardless of gender;
• • 2. Hematological malignancies confirmed by cytology, histology , or molecular biology (such as leukemia, lymphoma, multiple myeloma, etc.), who require subsequent anti-tumor treatment ( chemotherapy , hematopoietic stem cell transplantation, radiotherapy, or cellular immunotherapy ) ; control group
• • 1)≥ 18 years old , regardless of gender; 2)Non-cancer patients undergoing health checkups;
• • Exclusion criteria
• • 1. Pregnant women
• • 2. Those with severe mental disorders or language communication barriers
• • 3. Other circumstances that the researcher judges to be unsuitable for participation in this study